n(6)-carboxymethyllysine has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blazícek, P; Dzúrik, R; Gazdíková, K; Heidland, A; Schinzel, R; Sebeková, K; Spustová, V; Syrová, D | 1 |
| Amadio, L; Di Pippo, C; Iacobini, C; Menini, S; Oddi, G; Pricci, F; Pugliese, F; Pugliese, G; Ricci, C; Sorcini, M | 1 |
2 other study(ies) available for n(6)-carboxymethyllysine and Bright Disease
| Article | Year |
|---|---|
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Creatinine; Cystatin C; Cystatins; Diabetic Nephropathies; Female; Glomerulonephritis; Glycation End Products, Advanced; Homocysteine; Humans; Lipofuscin; Lysine; Male; Malondialdehyde; Middle Aged; Nephritis, Interstitial; Oxidative Stress; Polycystic Kidney Diseases; Ramipril; Severity of Illness Index; Statistics as Topic; Treatment Outcome | 2003 |
Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice.
Topics: Age Factors; Aging; Aldehydes; Animals; Body Weight; Dinoprost; Extracellular Matrix; Galectin 3; Glomerulonephritis; Glycation End Products, Advanced; Kidney Glomerulus; Lysine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |